Korean Journal of Psychosomatic Medicine (정신신체의학)

Korean Psychosomatic Society (한국정신신체의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Features Affecting Antipsychotic Prescription for Delirium Patients

섬망 환자에서 항정신병약물 처방에 영향을 주는 임상적 특징

  • Received : 2019.07.15
  • Accepted : 2019.09.10
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study was to investigate the clinical characteristics of antipsychotic medication prescription for the symptom control in patients with delirium. Methods : One hundred and eighty-five patients referred to consultation-liaison psychiatric services for delirium due to general medical condition were included in this study. All subjects were divided into two groups (antipsychotics users vs. antipsychotics nonusers), and comparison analyses on their clinical characteristics were performed. Results : One hundred and twenty nine patients (66.5%) used antipsychotics for their delirium, and 56 patients (30.3%) did not use antipsychotics. The history of psychotropic medication was more frequently observed in antipsychotic users (5.4% vs. 18.6%, χ2=5.498, p=0.022). Especially, the history of benzodiazepine use was significantly high in antipsychotics users. The total score and sub-items of delirium rating scale-severity items except for the psychomotor retardation item showed higher scores in antipsychotic users than in nonusers (all p<0.05). The total score of the delirium rating scale-diagnosis items was higher in antipsychotic users than in the nonusers (p=0.010). Conclusions : Delirium patients with more severe delirium symptoms and with more history of benzodiazepine use were treated with antipsychotics more frequently than those without. These findings imply that benzodiazepine may not only exacerbate delirium but be associated with aggression or psychomotor agitation that need immediate intervention. Clinicians may need to pay attention not only these external symptoms but also to hypoactive symptoms that may lead to misdiagnosis and undertreatment.

연구목적 본 연구에서는 섬망 증상 조절을 위한 항정신병약물 처방에 영향을 주는 임상적 특징을 알아보고자 한다. 방 법 연세대학교 원주세브란스 기독병원에 입원하여 정신건강의학과에 협진 의뢰된 환자 중, 일반신체질환에 의한 섬망으로 진단된 185명을 대상으로 후향적 의무기록을 조사하였다. 항정신병약물을 사용한 군과 사용하지 않은 군으로 구분하여 임상적 특성을 비교 분석하였다. 결 과 항정신병약물 사용군은 129명(66.5%)으로 정신과약물 사용력이 많았다. 특히 벤조디아제핀계 약물 사용력에서 두 군 간에 유의미한 차이를 보였다. 섬망평가척도 대다수에서 항정신병약물 사용군이 높은 점수를 보였다. 결 론 항정신병약물 사용군은 섬망의 외현 증상이 두드러지며 기저에 벤조디아제핀계 약물 복용력이 높았다. 이는 벤조디아제핀이 섬망의 경과와 외현 증상에 영향을 주었을 가능성이 있다. 임상 현장에서 예후에 영향을 줄 수 있는 섬망의 임상적 특징에 대한 이해가 축적되어야 할 것이다.

Keywords

References

  1. Sadock B, Ruiz P. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences: Walters Kluwer; 2015. p.697-704.
  2. Maldonado JR. Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium. Crit Care Clin 2017;33:461-519. https://doi.org/10.1016/j.ccc.2017.03.013
  3. Jones RN, Fong TG, Metzger E. Aging, brain disease, and reserve: implications for delirium. Am J Geriatr Psychiatry 2010;18:117-127. https://doi.org/10.1097/JGP.0b013e3181b972e8
  4. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. The Lancet 2014;383:911-922. https://doi.org/10.1016/S0140-6736(13)60688-1
  5. National Institute for Clinical Excellence. Delirium: prevention, diagnosis and management. London: NICE 2010.
  6. Park JS, Kim JJ, Park SJ, Kim SM, Park JY. Clinical course according to antipsychotics prescription pattern in delirium. Koean J Psychosomatic Med 2017;25:120-128.
  7. Ozbolt LB, Paniagua MA, Kaiser RM. Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc 2008;9:18-28. https://doi.org/10.1016/j.jamda.2007.08.007
  8. Thom RP, Mock CK, Teslyar P. Delirium in hospitalized patients: risks and benefits of antipsychotics. Cleve Clin J Med 2017;84:616-622. https://doi.org/10.3949/ccjm.84a.16077
  9. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: A systematic review and meta-analysis. J Am Geriatr Soc 2016;64:705-714. https://doi.org/10.1111/jgs.14076
  10. Lim HK, Paik IH, Oh K, Lee CU, Lee C. Comparison of the clinical efficacy and safety between intramuscular olanzapine and intramuscular haloperidol injection in the treatment of delirium. Korean J Psychopharmacol 2007;18:423-428.
  11. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297-301. https://doi.org/10.1016/S0033-3182(04)70170-X
  12. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004;30:444-449. https://doi.org/10.1007/s00134-003-2117-0
  13. Devlin JW, Roberts RJ, Fong JJ. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010;38:419-427. https://doi.org/10.1097/CCM.0b013e3181b9e302
  14. Lawlor PG, Bush SH. Delirium diagnosis, screening and management. Curr Opin in Support Palliat Care 2014;8:286. https://doi.org/10.1097/SPC.0000000000000062
  15. Bush SH, Kanji S, Pereira JL. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manage 2014;48:231-248. https://doi.org/10.1016/j.jpainsymman.2013.07.018
  16. American Psychiarty Association. Diagnostic and Statistical Manual of Mental Disorders, Foruth Edition (DSM-IV) Washington. DC, USA: American Psychiatric Association;2004.
  17. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Detection and documentation of dementia and delirium in acute geriatric wards. Gen Hosp Psychiatry 2004;26:31-35. https://doi.org/10.1016/j.genhosppsych.2003.08.003
  18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829. https://doi.org/10.1097/00003246-198510000-00009
  19. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC cancer 2004;4:94. https://doi.org/10.1186/1471-2407-4-94
  20. Austin SR, Wong Y-N, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson comorbidity index and Elixhauser score work. Med Care 2015;53:e65. https://doi.org/10.1097/MLR.0b013e318297429c
  21. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988;23:89-97. https://doi.org/10.1016/0165-1781(88)90037-6
  22. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 2001;13:229-242. https://doi.org/10.1176/jnp.13.2.229
  23. Kishi Y, Kato M, Okuyama T. Delirium: patient characteristics that predict a missed diagnosis at psychiatric consultation. Gen Hospital Psychiatry 2007;29:442-445. https://doi.org/10.1016/j.genhosppsych.2007.05.006
  24. Davis JM. Dose equivalence of the antipsychotic drugs. Catecholamines and Schizophrenia: Elsevier;1975. p.65-73.
  25. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-262. https://doi.org/10.1016/j.biopsych.2009.08.040
  26. Bush SH, Tierney S, Lawlor PG. Clinical assessment and management of delirium in the palliative care setting. Drugs 2017;77:1623-1643. https://doi.org/10.1007/s40265-017-0804-3
  27. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry 2018;33:1428-1457. https://doi.org/10.1002/gps.4823
  28. Triozzi PL, Goldstein D, Laszlo J. Contributions of benzodiazepines to cancer therapy. Cancer Invest 1988;6:103-111. https://doi.org/10.3109/07357908809077033
  29. Zaal IJ, Devlin JW, Hazelbag M. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med 2015;41:2130-2137. https://doi.org/10.1007/s00134-015-4063-z
  30. Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry 2013;21:1190-1222. https://doi.org/10.1016/j.jagp.2013.09.005
  31. Paton C. Benzodiazepines and disinhibition: a review. Psychiatric Bulletin 2002;26:460-462. https://doi.org/10.1192/pb.26.12.460
  32. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy: J Hum Pharmacol Drug Ther 2004;24:1177-1185. https://doi.org/10.1592/phco.24.13.1177.38089
  33. Kumar A, Bakhla AK, Gupta S, Raju BM, Prasad A. Etiologic and Cognitive Differences in Hyperactive and Hypoactive Delirium. The Primary Care Companion for CNS Disorders 2015:17.
  34. Kobayashi K, Takeuchi O, Suzuki M, Yamaguchi N. A retrospective study on delirium type. Psychiatry Clin Neurosci 1992;46:911-918. https://doi.org/10.1111/j.1440-1819.1992.tb02860.x
  35. Van Velthuijsen EL, Zwakhalen SM, Mulder WJ, Verhey FR, Kempen GI. Detection and management of hyperactive and hypoactive delirium in older patients during hospitalization: a retrospective cohort study evaluating daily practice. Int J Geriatr Psychiatry 2018;33:1521-1529. https://doi.org/10.1002/gps.4690
  36. Campbell N, Boustani MA, Ayub A. Pharmacological management of delirium in hospitalized adults-a systematic evidence review. J Gen Intern Med 2009;24:848-853. https://doi.org/10.1007/s11606-009-0996-7